Blood

Vol. 147, Issue 14 Issue 14 2026
20
Articles

Articles in this Issue

Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries

Alex Y. Ge, William B. Feldman, Martin F. Kaiser et al. Apr 02, 2026 pp. 1521-1531 10.1182/blood.2025030872

Abstract Chimeric antigen receptor (CAR) T cells are a major treatment advance for many patients with hematological malignancies, especially those with disease that has relapsed or...

When estrogen sparks clotting: the lactoferrin-FXI link

Dong Chen Apr 02, 2026 pp. 1518-1519 10.1182/blood.2025032335

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)( <i>CCND1</i> ; <i>IGH</i> )

Marcella Kaddoura, J. Erin Wiedmeier-Nutor, Vikas A. Gupta et al. Apr 02, 2026 pp. 1598-1610 10.1182/blood.2025029996

Abstract Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respo...

Venetoclax in myeloma: t(11;14) and what else?

Catherine Pellat-Deceunynck Apr 02, 2026 pp. 1513-1515 10.1182/blood.2025032670

Ultraprecision therapy for type 1 vs type 2 CALR+ MPN by dual epitope targeting that restores ruxolitinib sensitivity

Chloe A. L. Thompson-Peach, Daniel Thomas, Mara Dottore et al. Apr 02, 2026 pp. 1611-1623 10.1182/blood.2024027897

Abstract Somatic frameshift mutations in the gene encoding calreticulin (CALR) give rise to myelofibrosis and are classified as type 1 (del52) or type 2 (ins5) according to the deg...

SCD hemolysis aftershock: heme-IFN-CCL2 harms kidneys

Samit Ghosh Apr 02, 2026 pp. 1517-1518 10.1182/blood.2025032847

Access to CAR T-cell therapy across diverse global markets

Kristina Jenei Apr 02, 2026 pp. 1509-1510 10.1182/blood.2025032585

Breast hairy cell leukemia mimicking lobular breast carcinoma

Ilya V. Tsvetnov, Kirill A. Lyapichev Apr 02, 2026 pp. 1648-1648 10.1182/blood.2025032411

Transient SP140 inhibition unlocks hematopoietic stem cell fate from human pluripotent stem cells

Xingjie Liu, Zhiwei Zhang, Xinyu Cui et al. Apr 02, 2026 pp. 1584-1597 10.1182/blood.2025032084

Abstract Efficient derivation of transplantable hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs) is constrained by epigenetic silencing. Through a clustere...

Estrogen upregulates lactoferrin to induce hypercoagulability for hemostatic protection during pregnancy

Ruomei Cheng, Xiaopeng Tang, Xiaoshan Huang et al. Apr 02, 2026 pp. 1634-1646 10.1182/blood.2025030270

Abstract Venous thromboembolism (VTE) remains a leading contributor to maternal morbidity and mortality during pregnancy and the immediate postpartum period. Although pregnancy is...

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel

C. Michel Zwaan, Sarah K. Tasian, Richard Aplenc et al. Apr 02, 2026 pp. 1532-1561 10.1182/blood.2024027904

Abstract The European LeukemiaNet has periodically issued guidelines for the diagnosis and management of acute myeloid leukemia (AML) in adults. These consensus recommendations, mo...

Metamizole-induced agranulocytosis resulting in ecthyma gangrenosum after an AI chatbot query

Irene Tjaakje Schrijver, Yorick Sandberg Apr 02, 2026 pp. 1647-1647 10.1182/blood.2025032521

Arora J, Ayyappan S, Yin C, et al. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC. <i>Blood</i> . 2024;143(18):1816-1824.

Apr 02, 2026 pp. 1649-1649 10.1182/blood.2026033552

Turning off SP140 to turn on HSCs

Sarah Juster, Berthold Göttgens Apr 02, 2026 pp. 1511-1513 10.1182/blood.2025032459

Breaking new ground with antibody-drug conjugates in myeloma

Saad Z. Usmani Apr 02, 2026 pp. 1510-1511 10.1182/blood.2025032443

Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos et al. Apr 02, 2026 pp. 1574-1583 10.1182/blood.2025031629

Abstract The phase 1/2 BelaRd (belantamab mafodotin [belamaf], lenalidomide, and dexamethasone) study evaluated the efficacy and safety of belamaf combined with lenalidomide and de...

Heme-induced activation of the TLR3/TRIF–IFN-I–CCL2 pathway contributes to kidney injury in sickle cell disease

Yunfeng Liu, Sarah Shayo, Shan Su et al. Apr 02, 2026 pp. 1624-1633 10.1182/blood.2025031060

Abstract Sickle cell nephropathy (SCN) is a major clinical complication in sickle cell disease (SCD), yet its underlying mechanisms remain incompletely defined. Hemolysis, a hallma...

Double trouble: dual-epitope targeting of mutant CALR

Nicole S. Arellano, Shannon E. Elf Apr 02, 2026 pp. 1515-1516 10.1182/blood.2025032720

Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies

Hiroshi Kimura, Jeffrey I. Cohen Apr 02, 2026 pp. 1562-1573 10.1182/blood.2025032277

Abstract Chronic active Epstein-Barr virus (EBV; CAEBV) disease is an uncommon, often lethal T and/or natural killer (T/NK)–cell lymphoproliferative disorder that remains underreco...

Fan X, Xi Q. Flow cytometry–based evaluation of TRBC1/TRBC2 facilitates identification of indolent T-lymphoblastic proliferations. <i>Blood.</i> 2026;147(6):702.

Apr 02, 2026 pp. 1649-1649 10.1182/blood.2026033729

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page